The company
Sight Sciences, Inc.
SGHT · Nasdaq
SGHT stood above a rising 150-day average in 24 of the last 52 weekly readings, including each of the last 8 weeks. It is 39.7% above that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−9 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- In trend
- Weeks in an uptrend
- 8 in a row
- Industry in uptrend
- 27% -9 in 4 wk
- Insider buys, 12 months
- $254K
- Insider sales, 12 months
- $4.6M
- Officials’ trades on record
- 0
- Institutions holding
- 109 (+2)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 24 of 52 weeks.
Medical Devices: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| James RodbergChief Financial Officer | sold | 7,208at $8.85 | 2 Oct 2026filed 5 Oct 2026 |
| Alison BauerleinChief Operating Officer | sold | 25,260at $8.85 | 2 Oct 2026filed 5 Oct 2026 |
| Brenton TaylorEVP, Operations & R&D | sold | 2,988at $8.85 | 2 Oct 2026filed 5 Oct 2026 |
| Paul BadawiPresident and CEO | sold | 29,653at $9.05 | 1 Oct 2026filed 5 Oct 2026 |
| David BadawiChief Technology Officer | sold | 7,797at $9.05 | 1 Oct 2026filed 5 Oct 2026 |
| David BadawiChief Technology Officer | sold | 7,418at $5.51 | 6 Jul 2026filed 6 Jul 2026 |
| Jeremy B. HaydenChief Legal Officer | sold | 12,733at $5.51 | 6 Jul 2026filed 6 Jul 2026 |
| Alison BauerleinChief Operating Officer | sold | 24,184at $5.36 | 2 Jul 2026filed 6 Jul 2026 |
| James RodbergChief Financial Officer | sold | 6,902at $5.36 | 2 Jul 2026filed 6 Jul 2026 |
| Paul BadawiPresident and CEO | sold | 28,684at $5.42 | 1 Jul 2026filed 6 Jul 2026 |
| Brenton TaylorEVP, Operations & R&D | sold | 2,829at $5.42 | 1 Jul 2026filed 6 Jul 2026 |
| Staffan EncrantzDirector, 10% owner | bought | 14,100at $4.88 | 10 Jun 2026filed 11 Jun 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| Long Focus Capital Management, LLCadded · filed 14 Aug 2026 | 3,844,100$20.8M | +250,000+7.0% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 3,083,108$16.7M | +251,176+8.9% |
| Americana Partners, LLCadded · filed 5 Aug 2026 | 1,679,069$9.1M | +520.0% |
| Pathstone Holdings, LLCreduced · filed 13 Aug 2026 | 1,678,980$9.1M | -718,352−30.0% |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 1,573,815$8.5M | +121,125+8.3% |
| B Group, Inc.unchanged · filed 14 Aug 2026 | 970,000$3.7M | 00.0% |
| GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026 | 958,565$5.2M | +43,121+4.7% |
| STATE STREET CORPadded · filed 7 Aug 2026 | 835,452$4.5M | +424+0.1% |
| AQR CAPITAL MANAGEMENT LLCadded · filed 14 Aug 2026 | 397,558$2.2M | +259,041+187.0% |
| DIMENSIONAL FUND ADVISORS LPadded · filed 11 Aug 2026 | 383,512$2.1M | +41,831+12.2% |
News
No headline names it lately.
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.